State gets $1.7 million in diabetes drug settlement

Hartford - Connecticut is getting nearly $1.7 million to settle claims that British drug maker GlaxoSmithKline LLC deceptively promoted the diabetes drug Avandia. The payment is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.

Attorneys general say GlaxoSmithKline misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices.

GlaxoSmithKline doesn't admit any wrongdoing.

- Associated Press


Loading comments...
Hide Comments